Compugen Expands Its Intellectual Property Portfolio With New U.S. Patent Covering Triple Combination Use Of COM902 (Reduced FC Anti-TIGIT) With Anti-PD-1 And Anti-PVRIG Antibodies
Compugen Expands Its Intellectual Property Portfolio With New U.S. Patent Covering Triple Combination Use Of COM902 (Reduced FC Anti-TIGIT) With Anti-PD-1 And Anti-PVRIG Antibodies
compugen醫療通過新的美國專利擴展了其知識產權組合，涵蓋了COM902（降低的FC抗TIGIT）與抗PD-1和抗PVRIG抗體的三聯組合使用
The company announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent covering method of use for COM902, the Company's potential best-in-class reduced Fc, clinical stage antibody targeting TIGIT, and additional TIGIT backup antibodies in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer.
公司宣佈，美國專利商標局（USPTO）已授予公司一項新專利，該專利涵蓋了 COM902 的使用方法。這是公司潛在的最佳類 Fc 降低型抗體，處於臨床階段，靶向 TIGIt，並且與任何抗 PD-1 抗體和任何抗 PVRIG 抗體以三重組合形式用於癌症治療。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間